Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

This study aimed to evaluate the expression and clinical significance of budding uninhibited by benzimidazole 1 (BUB1) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) in endometrial carcinoma (EC). BUB1 and BUBIB expressions were evaluated by bioinformatics. Protein expression, clinica...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 14; no. 1; pp. 17084 - 11
Main Authors: Zhang, Huicong, li, yuhao, Lu, Huixia
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 24.07.2024
Nature Publishing Group
Nature Portfolio
Subjects:
631/114
631/67
Benzimidazoles
Bioinformatics
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
BUB1
BUB1B
Cancer
CD4 antigen
CD8 antigen
Cell Cycle Proteins
Cell Line, Tumor
Cell migration
Cell Movement - genetics
Clinicopathological characteristics
Development
Disease-Free Survival
Endometrial cancer
Endometrial Neoplasms - genetics
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Endometrium
Endothelial cells
Female
Gene expression
Gene Expression Regulation, Neoplastic
Humanities and Social Sciences
Humans
Immunotherapy
Infiltration
Kinases
Lymphocytes T
Medical prognosis
Metastases
Middle Aged
multidisciplinary
Phenotypes
Prognosis
Protein Serine-Threonine Kinases - genetics
Protein Serine-Threonine Kinases - metabolism
Protein-serine/threonine kinase
Science
Science (multidisciplinary)
siRNA
Uterine cancer
Development
BUB1B
Clinicopathological characteristics
Prognosis
Endometrial cancer
BUB1
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to evaluate the expression and clinical significance of budding uninhibited by benzimidazole 1 (BUB1) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) in endometrial carcinoma (EC). BUB1 and BUBIB expressions were evaluated by bioinformatics. Protein expression, clinical features, prognosis and immune cell infiltration were explored in 20 EC tumors. siRNA was used to evaluate BUB1 and BUBIB function in EC cells. BUB1 and BUBIB were highly expressed in 26 cancers. BUB1 was associated with overall survival (OS) in eight cancers and disease-free survival in ten; BUB1B was associated with OS in nine cancers and DFS in eleven. BUB1 and BUBIB exhibited high frequencies of gene changes (mainly mutations, > 5%) in cancer. BUB1 was negatively correlated and BUB1B was positively correlated with cancer-associated fibroblasts and endothelial cell infiltration. BUB1 and BUBIB knockdown decreased migration and invasion in EC cells. High BUB1 expression correlated with tumor malignant phenotypes ( P  < 0.05). High BUB1 mRNA expression reduced OS ( P  = 0.00036) and recurrence-free survival ( P  = 0.0011). High BUB1B mRNA expression reduced OS ( P  = 0.0024). BUB1/BUB1B correlated with activated CD8 + T and CD4 + T cell infiltration. BUB1 and BUBIB are highly expressed and correlated with clinicopathological characteristics in EC. BUB1 and BUBIB are potential prognosis markers and immunotherapy targets.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-67528-2